CIPLA LTD. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Download	< Back
21 May 2020
Cipla Limited receives final approval for generic version of Migranal (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) with a Competitive Generic Therapy Designation
View all announcements for CIPLA LTD.	Source: BSE India

ALL MONEYWIZ PAGES

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us